(Q33394188)

26 July 2017

1 reference

title

Heparin-induced thrombocytopenia: present and future (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

Adam Cuker

1

1 reference

26 July 2017

publication date

1 April 2011

1 reference

Journal of Thrombosis and Thrombolysis

26 July 2017

published in

1 reference

26 July 2017

volume

31

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

353-366

1 reference

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Studies on the frequency of heparin-associated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-associated thrombocytopenia: case report and prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Further characterization of antibody and antigen in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Characterization of the humoral immune response in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

New approaches to the diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin‐induced thrombocytopenia: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Temporal aspects of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Delayed-onset heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Delayed-onset heparin-induced thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Blood product use in cardiac revascularization: comparison of on- and off-pump techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

A 14-year study of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Case report: heparin-induced thrombocytopenia--a complication presenting to the vascular radiologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Transient global amnesia associated with acute heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The HIT Expert Probability (HEP) Score: a novel pre‐test probability model for heparin‐induced thrombocytopenia based on broad expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

What is the potential for overdiagnosis of heparin-induced thrombocytopenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Clinical practice. Heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Argatroban anticoagulation in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Agents for the treatment of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0569-6

Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories.

21 January 2018

1 reference

12 December 2020

Safety of low-molecular-weight heparin in pregnancy: a systematic review.

1 reference

12 December 2020

A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study

1 reference

12 December 2020

Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

1 reference

12 December 2020

Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.

1 reference

12 December 2020

A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT)

1 reference

12 December 2020

Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies

1 reference

12 December 2020

Antigens involved in heparin-induced thrombocytopenia.

1 reference

12 December 2020

Heparin-induced thrombocytopenia associated with fondaparinux

1 reference

12 December 2020

Heparin-induced thrombocytopenia in renal failure

1 reference

12 December 2020

The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients

1 reference

12 December 2020

Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

1 reference

12 December 2020

Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly

1 reference

12 December 2020

Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients.

1 reference

12 December 2020

Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke

1 reference

12 December 2020

Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.

1 reference

12 December 2020

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.

1 reference

12 December 2020

Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes

1 reference

12 December 2020

Heparin induced thrombocytopenia: a prospective study

1 reference

12 December 2020

High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis

1 reference

12 December 2020

A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia

1 reference

12 December 2020

Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin

1 reference

12 December 2020

A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia

1 reference

12 December 2020

The white clot syndrome or heparin associated thrombocytopenia and thrombosis (WCS or HATT) (26 cases).

1 reference

12 December 2020

A diagnostic test for heparin-induced thrombocytopenia

1 reference

12 December 2020

PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model

1 reference

12 December 2020

Clinical presentation of heparin-induced thrombocytopenia.

1 reference

12 December 2020

Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin.

1 reference

12 December 2020

Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia

1 reference

12 December 2020

Simple scoring system for early management of heparin-induced thrombocytopenia

1 reference

12 December 2020

Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen

1 reference

12 December 2020

Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004

1 reference

12 December 2020

Impact of the patient population on the risk for heparin-induced thrombocytopenia.

1 reference

12 December 2020

1 reference

12 December 2020

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.

1 reference

12 December 2020

Heparin-induced skin lesions

1 reference

12 December 2020

Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin

1 reference

12 December 2020

Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods

1 reference

12 December 2020

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy

1 reference

12 December 2020

ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?

1 reference

12 December 2020

Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study

1 reference

12 December 2020

10.1007/S11239-011-0569-6

Identifiers

DOI

1 reference

26 July 2017

1 reference